U.S., Jan. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07379125) titled 'Therapeutic RSK1 Targeting in Myelofibrosis' on Jan. 23.
Brief Summary: This is a phase Ib study evaluating PMD-026, an oral inhibitor of ribosomal protein S6 kinase A1 (RSK1), in participants with myelofibrosis (MF).The dose escalation portion utilizes a standard 3+3 design to evaluate two dose levels with an additional dose de-escalation portion to identify the recommended phase II dose (RP2D); subsequently, an additional 6 patients will be enrolled in the dose expansion portion evaluating the efficacy of PMD-026.
Study Start Date: March 31
Study Type: INTERVENTIONAL
Condition:
Myelofibrosis
Intervention:
DRUG: PMD-026
PMD-...